Table 2 Reason for NTZ discontinuation.

From: Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years

Reason for discontinuation

N (%)

JCV positive

58 (55.2)

SPMS

18 (17.1)

Disease activity

8 (7.6)

NAbs

7 (6.7)

By request of patient

6 (5.7)

Comorbidity

6 (5.7)

Pregnancy

4 (3.8)

PML

3 (2.9)

Adverse event

3 (2.9)

  1. 105 patients discontinued NTZ. Those patients who stopped treatment due to pregnancy are planned to restart NTZ after delivery.
  2. JCV positive positive for Anti-JC-Virus antibodies, SPMS secondary progressive multiple sclerosis, NAbs neutralizing antibodies, PML progressive multifocal leukoencephalopathy.
Back to article page